<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0156)http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0202/0202_q1/0202_i3?f=templates&fn=document-frame.htm&q=freemantle&x=Simple&2.0 -->
<HTML><HEAD><TITLE>Clinical Evidence</TITLE>
<META http-equiv=Content-Type content="text/html; charset=windows-1252"><LINK 
href="0202_i3_files/bmj.css" type=text/css rel=stylesheet>
<META content="MSHTML 5.50.4807.2300" name=GENERATOR>
<script language="JavaScript">
<!--
function MM_goToURL() { //v3.0
  var i, args=MM_goToURL.arguments; document.MM_returnValue = false;
  for (i=0; i<(args.length-1); i+=2) eval(args[i]+".location='"+args[i+1]+"'");
}
//-->
</script>
</HEAD>
<BODY topMargin=0>
<TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="0202_i3_files/0202_i3.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular 
            disorders</SECTION></SPAN><IMG height=10 
            src="0202_i3_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR><SPAN class=localhead id=localhead><TOPIC>Acute 
            myocardial infarction</TOPIC><IMG height=10 
            src="0202_i3_files/spacer.gif" width=10 align=absMiddle 
            border=0></SPAN></TD></TR>
        <TR>
          <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30>Shamir Mehta<IMG height=10 src="0202_i3_files/spacer.gif" width=10 
            align=absMiddle border=0></TD>
        </TR></TBODY></TABLE><BR>
      <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Treatments</H1>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question>&nbsp;<B>Which treatments improve 
            outcomes in acute myocardial 
      infarction?</B></TD></TR></TBODY></TABLE><BR><A name=I3>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">ß 
      Blockers</H2>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>ß Blockers</B></TD></TR></TBODY></TABLE></A>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR>
          <TD><A name=I3-SUMSTATEMENT><B>
            <P style="MARGIN-LEFT: 3px" align=justify>Systematic reviews of RCTs 
            have found that oral ß blockers given within hours of infarction 
            reduce both mortality and reinfarction in people with AMI. Adding ß 
            blockers to thrombolytic treatment confers additional benefit. Most 
            benefit is obtained from long term use of ß 
        blockers.</P></B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A 
            name=I3-BENEFITS><B>Benefits: </B></A></FONT><B>Given within hours 
              of infarction:</B> We found three systematic reviews (search date 
              1997, <A 
            href="#references">[16]</A> search date not stated, <A 
            href="#references">[17]</A> search date 1987 <A 
            href="#references">[18]</A> ) of early use of ß blockers. The older 
              reviews identified 27 RCTs and found that, within 1 week of treatment, 
              ß blockers significantly reduced the risk of death and major vascular 
              events (RR for the combined outcome of death, non-fatal cardiac 
              arrest, or non-fatal reinfarction 0.84, 1110 events <EM>v</EM> 1298 
              events, 95% CI not available, P&nbsp;&lt;&nbsp;0.001). The largest 
              of the RCTs (16&nbsp;027 people with AMI) compared intravenous atenolol 
              5–10&nbsp;mg given immediately followed by 100&nbsp;mg orally given 
              daily for 7 days versus standard treatment (no ß blocker). <A 
            href="#references">[19]</A> After 7 days, atenolol reduced vascular 
              mortality compared with control (3.9% with atenolol <EM>v</EM> 4.6% 
              with control; ARR 0.7%; RR 0.85, 95% CI 0.73 to 0.88; NNT 147). 
              The RCT found more benefit in people with ECG evidence of AMI at 
              entry (in people with ECG suggesting anterior infarction, inferior 
              infarction, both, or bundle branch block, AR of death 5.33% on atenolol, 
              6.49% for controls; ARR 1.16%; NNT 86, 95% CI not available). People 
              older than 65 years and those with large infarcts had the most benefit. 
              <A 
            href="#references">[19]</A> The recent systematic review (search date 
              1997, 82 RCTs, 54 234 people) <A 
            href="#references">[16]</A> separately analysed 51 short term RCTs 
              (up to 6 weeks after the onset of pain) and 31 long term RCTs. Most 
              of the RCTs did not include thrombolysis. In the short term studies 
              seven RCTs reported no deaths, and many reported only a few. Meta-analysis 
              of the RCTs that reported at least one death found that ß blockers 
              versus placebo reduced mortality, but the reduction was not significant 
              in the short term (ARR 0.4%, OR 0.96, 95% CI 0.85 to 1.08).<font color="#FF0000"> 
              In the longer term RCTs, ß blockers versus placebo significantly 
              reduced mortality over 6 months to 4 years (OR 0.77, 95% CI 0.69 
              to 0.85). About 84 people would need treatment for 1 year to avoid 
              one death. No significant difference in effectiveness was found 
              between different types of ß blocker (based on cardioselectivity 
              or intrinsic sympathomimetic activity). Most evidence was obtained 
              with propranolol, timolol, and metoprolol.</font> <B>In people receiving 
              thrombolytic treatment: </B>We found one RCT (1434 people with AMI), 
              which compared early versus delayed metoprolol in people who had 
              been given thombolysis (tPA). <A 
            href="#references">[20]</A> Early treatment began on day 1 (intravenous 
              then oral) and delayed treatment on day 6 (oral). At 6 days, people 
              receiving early treatment had significantly lower rates of reinfarction 
              (AR 2.7% early<EM><EM>v</EM></EM>5.1% delayed, 95% CI not available, 
              P&nbsp;=&nbsp;0.02) and recurrent chest pain (AR 18.8%<EM><EM>v</EM></EM>24.1%, 
              P&nbsp;&lt;&nbsp;0.02). There were no early (6 days) or late (1 
              year) differences observed in mortality or left ventricular ejection 
              fraction between the two groups. <B>Long term use:</B> <A 
            href="../secondary_MI_and_Metoprolol_CE.htm?f=id&id=0206_I3&t=document-frame.htm&2.0&p=" target="_blank"><b><font color="#FF0000">See 
              ß blockers under secondary prevention of ischaemic cardiac events</font></b></A>.</P>
          </TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I3-HARMS><B>Harms: </B></A></FONT>People 
              with asthma or severe congestive cardiac failure were excluded from 
              most trials. Many of the early trials tended to enrol people at 
              low risk of death soon after AMI. In people given immediate rather 
              than delayed ß blockers following tPA, there was a non-significantly 
              increased frequency of heart failure during the initial admission 
              to hospital (15.3%<EM> v</EM> 12.2%, P&nbsp;=&nbsp;0.10). <A 
            href="#references">[20]</A> The presence of first degree heart block 
              and bundle branch block was associated with an increased frequency 
              of adverse events.</P>
          </TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I3-COMMENT><B>Comment: 
              </B></A></FONT>ß Blockers may reduce rates of cardiac rupture and 
              ventricular fibrillation. This may explain why people older than 
              65 years and those with large infarcts benefited most, as they also 
              have higher rates of these complications. The trials were mostly 
              conducted in the prethrombolytic era. The trial comparing early 
              versus delayed ß blockade following thrombolysis was too small to 
              rule out an effect on mortality of ß blockers when added to thrombolysis. 
              <A 
            href="#references">[20]</A> </P>
          </TD></TR></TBODY></TABLE><BR><A name=references></A>
      <TABLE cellSpacing=0 cellPadding=0 border=0>
        <TBODY>
        <TR>
          <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
          <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD></TR>
        <TR>
          <TD class=key-message id=key-message width=90 
            bgColor=#404040><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE cellPadding=2 width="100%" align=center>
        <TBODY>
        <TR><A class=reference id=reference name=REF16></a>
          <TD class=reference id=reference vAlign=top width=15 height="47">16. 
          </TD>
          <TD class=reference id=reference vAlign=top width="100%" height="47"><a href="#" onClick="MM_goToURL('parent.frames[\'main_banner\']','../../Banners/PubMed.htm','parent.frames[\'main_content\']','../../Original%20papers/MI%20and%20Metoprolol_content.html#Freemantle');return document.MM_returnValue">Freemantle 
            N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial 
            infarction: systematic review and meta regression analysis. <EM>BMJ 
            </EM>1999;318:1730–1737. Search date 1997; primary sources Medline, 
            Embase, Biosis, Healthstar, Sigle, IHTA, Derwent drug file, dissertation 
            abstracts, Pascal, international pharmaceutical abstracts, science 
            citation index, and handsearch of reference lists.</a></TD>
        </TR>
        <TR><A class=reference id=reference name=REF17></a>
          <TD class=reference id=reference vAlign=top width=15 height="44">17. 
          </TD>
          <TD class=reference id=reference vAlign=top width="100%" height="44"><a href="../../Original%20papers/MI%20and%20Metoprolol_OP.html#Yusuf" target="_top" onClick="MM_goToURL('parent.frames[\'main_banner\']','../../Banners/PubMed.htm','parent.frames[\'main_content\']','../../Original%20papers/MI%20and%20Metoprolol_content.html#Yusuf');return document.MM_returnValue">Yusuf 
            S, Peto R, Lewis S, et al. Beta-blockade during and after myocardial 
            infarction: an overview of the randomized trials. <EM>Prog Cardiovasc 
            Dis</EM> 1985;27:355–371. Search date not stated; primary sources 
            computer-aided search of the literature; manual search of reference 
            lists; and enquiries to colleagues about relevant papers.</a></TD>
        </TR>
        <TR><A class=reference id=reference name=REF18></a>
          <TD class=reference id=reference vAlign=top width=15>18. </TD>
          <TD class=reference id=reference vAlign=top width="100%"><a href="../../Original%20papers/MI%20and%20Metoprolol_OP.html#Sleight" target="_top" onClick="MM_goToURL('parent.frames[\'main_banner\']','../../Banners/PubMed.htm','parent.frames[\'main_content\']','../../Original%20papers/MI%20and%20Metoprolol_content.html#Sleight');return document.MM_returnValue">Sleight 
            P for the ISIS Study Group. Beta blockade early in acute myocardial 
            infarction. <EM>Am J Cardiol</EM> 1987;60:6A–12A.</a></TD>
        </TR>
        <TR><A class=reference id=reference name=REF19></a>
          <TD class=reference id=reference vAlign=top width=15>19. </TD>
          <TD class=reference id=reference vAlign=top width="100%"><a href="../../Original%20papers/MI%20and%20Metoprolol_OP.html#ISIS" target="_top" onClick="MM_goToURL('parent.frames[\'main_banner\']','../../Banners/PubMed.htm','parent.frames[\'main_content\']','../../Original%20papers/MI%20and%20Metoprolol_content.html#ISIS');return document.MM_returnValue">First 
            International Study of Infarct Survival (ISIS-1). Randomised trial 
            of intravenous atenolol among 16&nbsp;027 cases of suspected acute 
            myocardial infarction. <EM>Lancet</EM> 1986;ii:57–66.</a></TD>
        </TR>
        <TR><A class=reference id=reference name=REF20></a>
          <TD class=reference id=reference vAlign=top width=15>20. </TD>
          <TD class=reference id=reference vAlign=top width="100%"><a href="../../Original%20papers/MI%20and%20Metoprolol_OP.html#Roberts" target="_top" onClick="MM_goToURL('parent.frames[\'main_banner\']','../../Banners/PubMed.htm','parent.frames[\'main_content\']','../../Original%20papers/MI%20and%20Metoprolol_content.html#Roberts');return document.MM_returnValue">Roberts 
            R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade 
            following thrombolytic therapy in patients with acute myocardial infarction: 
            results of the thrombolysis in myocardial infarction (TIMI) II-B study. 
            <EM>Circulation</EM> 1991;83:422–437.</a></TD>
        </TR></TBODY></TABLE>
      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
          <TD align=right width="50%"><IMG 
            alt="BMJ - Clinical Evidence" src="../ce-bmj-small-banner%5B1%5D.gif" 
            border=0 width="89" height="44"></TD>
        </TR>
        <TR>
          <TD align=left width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">Issue 5 - June 
          2001</SPAN></TD>
          <TD align=right width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</SPAN></TD>
        </TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0202.PDF"; 
</SCRIPT>
      </TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT type=hidden value=1 name=LPHitCount> 
</FORM></BODY></HTML>
